Parkinson's: A Weekly Injection Breakthrough

Parkinson's Disease: A Leap Forward in Treatment with Weekly Injections

For millions living with Parkinson's disease, the daily regimen of multiple oral medications can be a significant burden. The constant need to remember dosages, the potential for missed pills, and the resulting fluctuations in symptom control can profoundly impact quality of life. However, a groundbreaking development from the University of South Australia (UniSA) promises to change this landscape. Researchers have developed a novel, long-acting injectable formulation that delivers key Parkinson's medications, levodopa and carbidopa, steadily over an entire week, offering a potential "game-changer" for patient care.

Understanding the Challenge of Parkinson's Treatment

Parkinson's disease is a progressive neurodegenerative disorder affecting movement. Its hallmark symptoms include tremors, rigidity, slowness of movement, and postural instability. While there is currently no cure, the cornerstone of management involves medications that replenish dopamine levels in the brain. Levodopa, often combined with carbidopa, is the most effective drug for managing these symptoms. However, levodopa has a short half-life, meaning it is quickly metabolised by the body. This necessitates frequent oral administration – often three to five times a day – to maintain therapeutic levels and consistent symptom control. This frequent dosing schedule presents several challenges:

• Patient Adherence: Remembering to take multiple doses at precise times can be difficult, especially for elderly patients or those with cognitive impairments. Even a single missed dose can lead to a noticeable deterioration in motor symptoms.
• Fluctuating Drug Levels: The peaks and troughs in medication levels can result in "on-off" phenomena, where symptoms fluctuate unpredictably, impacting daily activities and overall well-being.
• Swallowing Difficulties: Some individuals with Parkinson's experience dysphagia (difficulty swallowing), making the ingestion of multiple pills a daily struggle.
• Reduced Quality of Life: The constant preoccupation with medication schedules can detract from the individual's ability to live a full and spontaneous life.

The Innovative Weekly Injectable Solution

Recognising these limitations, scientists at UniSA, led by Professor Sanjay Garg and PhD student Deepa Nakmode, have engineered a sophisticated injectable formulation designed to overcome the drawbacks of oral levodopa and carbidopa. This innovative treatment involves a biodegradable solution that, once injected under the skin or into muscle tissue, forms an implant. This implant then steadily releases the medication over a seven-day period.

The core of this innovation lies in the careful combination of two FDA-approved biodegradable polymers: poly-lactic-co-glycolic acid (PLGA) and Eudragit L-100, a pH-sensitive polymer. This blend allows for a controlled and sustained release of both levodopa and carbidopa. Extensive laboratory testing has yielded highly promising results:

Furthermore, the formulation demonstrated minimal toxicity in cell viability tests and can be administered using a fine 22-gauge needle, minimising patient discomfort and eliminating the need for surgical intervention. The system's design also allows for flexibility, with the potential to tune the release period from a few days to several weeks, depending on specific therapeutic needs.

The "Game-Changer" for Parkinson's Patients

The implications of this research are profound. By reducing the dosing frequency from multiple times a day to a single weekly injection, this new formulation offers several significant benefits for individuals living with Parkinson's disease:

• Improved Adherence: A weekly injection is considerably easier to manage than a daily regimen of multiple pills, significantly reducing the risk of missed doses and improving overall compliance.
• Consistent Drug Levels: The sustained release mechanism ensures more stable plasma concentrations of levodopa and carbidopa, leading to smoother symptom control and a reduction in "on-off" fluctuations. This translates to more predictable daily functioning.
• Enhanced Freedom and Quality of Life: Patients can experience greater freedom from the constant burden of medication management, allowing them to focus more on living their lives. As one patient, Peter Willis, who was diagnosed with Parkinson's ten years ago, noted, "Having to remember four every day is a pain in the arse." A weekly injection would offer considerable relief.
• Potential for Reduced Side Effects: More stable drug levels may also lead to a reduction in certain side effects associated with the peaks and troughs of oral medication.

Olivia Nassaris, CEO of Parkinson's Australia, has hailed the findings as a "breakthrough," noting the lack of significant advancements in Parkinson's medications in recent years. The current reliance on oral medications means this new injectable therapy represents a significant step forward, with no comparable treatment currently available on the market.

The Science Behind the Innovation

The development of this in-situ forming implant system is a testament to meticulous research and formulation science. The chosen polymers, PLGA and Eudragit L-100, work synergistically. PLGA is a well-established biodegradable polymer used in many drug delivery systems, known for its biocompatibility and predictable degradation. Eudragit L-100, being pH-sensitive, responds to the environment in the body, influencing the rate at which the medication is released. This tailored combination ensures that the levodopa and carbidopa are delivered at a controlled and consistent rate over the entire week.

The research team conducted rigorous in-vitro release studies, confirming that the formulation released approximately 92% of levodopa and 81% of carbidopa within seven days. Crucially, the implant itself degraded by over 80% within the same timeframe, indicating that it does not accumulate in the body. The injectability was also a key consideration, with the formulation designed to pass through a fine needle, making administration as comfortable and accessible as possible.

What are the next steps?

While laboratory tests have confirmed the effectiveness and safety profile of the formulation, the critical next phase involves clinical trials in humans. UniSA scientists are aiming to commence animal testing within the next six months, pending necessary ethics approvals. Following successful animal trials, the research team hopes to initiate human clinical trials in the near future. Concurrently, they are exploring commercialisation opportunities to bring this life-changing therapy to patients as swiftly as possible. The research has been published in the journal Drug Delivery and Translational Research, and the innovation has been filed for an Australian patent.

Beyond Parkinson's: A Future for Chronic Disease Management

The potential of this long-acting injectable technology extends far beyond Parkinson's disease. Professor Garg highlighted that the underlying system can be adapted to deliver a wide range of medications for other chronic conditions. This includes:

• Cancer: Delivering chemotherapy agents more effectively and with fewer side effects.
• Diabetes: Providing sustained release of insulin or other antidiabetic drugs.
• Neurodegenerative Disorders: Offering new delivery methods for other neurological conditions.
• Pain Management: Enabling long-term pain relief through controlled drug release.
• Chronic Infections: Ensuring consistent levels of antibiotics or antivirals.

This versatility underscores the transformative potential of this research, not just for Parkinson's patients, but for millions worldwide suffering from various chronic illnesses. The ability to simplify treatment regimens, improve patient adherence, and enhance therapeutic outcomes marks a significant advancement in pharmaceutical innovation.

Frequently Asked Questions

What is the new Parkinson's injection?

It is a long-acting injectable formulation that delivers levodopa and carbidopa, key medications for Parkinson's, steadily over seven days. It is designed to replace the need for multiple daily oral doses.

How does it work?

The biodegradable solution is injected under the skin or into muscle. It forms an implant that gradually releases the medication over a week, maintaining consistent drug levels in the body.

What are the benefits for patients?

Benefits include improved adherence due to less frequent dosing, more stable symptom control, reduced burden of remembering multiple pills, and potentially an improved quality of life.

Is it safe?

Laboratory tests have indicated a favourable safety profile with minimal toxicity. However, human clinical trials are necessary to confirm safety and efficacy in patients.

When will it be available?

The research is still in its early stages. Following successful animal and human clinical trials, and regulatory approvals, it may become available. The timeline for this is not yet confirmed.

Can this technology be used for other diseases?

Yes, the researchers believe the technology can be adapted for a wide range of chronic conditions requiring long-term drug delivery, such as cancer, diabetes, and pain management.

This pioneering work from the University of South Australia represents a beacon of hope for the Parkinson's community and a significant stride forward in the ongoing quest for better treatments for chronic diseases. The prospect of a simple, weekly injection offering consistent relief and greater freedom is a truly exciting development.

If you want to read more articles similar to Parkinson's: A Weekly Injection Breakthrough, you can visit the Automotive category.